CCG
MRNA icon

Cypress Capital Group’s Moderna MRNA Stock Holding History

Cypress Capital Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,988
Closed -$363K – 302
2023
Q2 		$363K Buy
2,988
+23
+0.8% +$3.07K 0.05% 241
2023
Q1 		$455K Buy
2,965
+184
+7% +$30.4K 0.07% 216
2022
Q4 		$500K Buy
2,781
+612
+28% +$100K 0.08% 213
2022
Q3 		$257K Sell
2,169
-47
-2% -$7.13K 0.04% 251
2022
Q2 		$317K Buy
2,216
+463
+26% +$66.2K 0.05% 242
2022
Q1 		$304K Buy
1,753
+732
+72% +$123K 0.04% 259
2021
Q4 		$259K Sell
1,021
-1,010
-50% -$295K 0.03% 271
2021
Q3 		$782K Buy
2,031
+411
+25% +$152K 0.11% 168
2021
Q2 		$380K Sell
1,620
-102
-6% -$18.2K 0.05% 232
2021
Q1 		$226K Sell
1,722
-830
-33% -$120K 0.03% 260
2020
Q4 		$267K Buy
+2,552
New +$258K 0.04% 237

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Cypress Capital Group's MRNA Position: Q3 2023 in Review

Cypress Capital Group sold out of Moderna (MRNA) in Q3 2023, closing a stake of 2,988 shares — an estimated $363K sold.

Cypress Capital Group first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $782K in Q3 2021. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Cypress Capital Group reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Cypress Capital Group sold 2,988 Moderna shares in Q3 2023, an estimated $363K.
  • Cypress Capital Group first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • Cypress Capital Group's Moderna position peaked at $782K in Q3 2021.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Cypress Capital Group's 13F filing for Q3 2023, filed 2 Nov 2023.